24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
Fax: (361)578-5500
Regular Hours: M-Fri 8am - 5pm
Every 3rd Thurs of the Month - Extended Hours Until 7 pm

Medical Disorders
Resources
Basic InformationLookupsLatest News
Ibuprofen, Similar Painkillers Won't Raise Risks for COVID PatientsObesity Raises Odds for Many Common CancersAsthma Attacks Plummeted During PandemicWhy Sleep Raises Risk for Sudden Death in People With EpilepsyLockdown Loneliness Making Things Even Tougher for Cancer PatientsCOVID Vaccines May Still Leave Organ Transplant Recipients UnprotectedPfizer, Moderna or J&J? An Expert Answers Your QuestionsHow Summer Camps Can Shield Your Kids from Allergies, Asthma & COVIDCould Your Child Have a Heart Defect? Know the Warning SignsGene Tied to Balding May Also Raise COVID Risks for MenTime Spent in ICU Linked to Higher Odds for Suicide LaterState of Mind Matters for Survival After Heart AttackFailing Kidneys Could Bring Higher Dementia RiskAir Pollution Can Harm Kids' Hearts for a LifetimePoll Finds Many Parents Hesitant to Get Younger Kids VaccinatedObesity More Deadly for Men Than Women When COVID StrikesIsrael Study: Pfizer Vaccine Gives 95% Protection Against Illness, Hospitalization & DeathReal-World Studies Show Pfizer Vaccine Shields Against COVID Variants1 in 4 U.S. Teens Has Had a Concussion: StudyWhat's the Right Amount of Sleep for a Healthy Heart?U.S. COVID Outlook Shows Big Improvement by July'Prediabetes' Raises Odds for Heart Attack, StrokeA Vitamin Could Be Key to Women's Pain After Knee ReplacementBiden Sets New Goal of Vaccinating 70% of Americans by July 4Wildfires Are Changing the Seasonal Air Quality of the U.S. WestMany Americans Wrong About Sun's Skin Cancer Dangers: PollNot Just About Antibodies: Why mRNA COVID Vaccines May Shield From VariantsYou Got Your COVID Shot: What to Do With That Vaccine CardFDA Plans to OK Pfizer Vaccine for Those Aged 12 and UpAHA News: As Pre-Pandemic Activities Return, So Does AnxietyCOVID Anxieties Still High for Americans: PollCOVID Vaccination in Pregnancy May Pass Helpful Antibodies to BabyWhy U.S. Hispanics Got COVID at Higher Rates: Their JobsHerd Immunity for Americans May Be an Elusive Goal, Experts SayUrgent Care or the ER? Which Should You Choose?Needle Anxiety Behind J&J COVID Vaccine Reaction Clusters: Study1 in 5 Patients on Kidney Dialysis Say No to COVID-19 Vaccine: StudyYoung, Immune-Compromised Patients Are Hotspots for Coronavirus Mutations: StudyYour Blood Type Might Raise Odds for Certain Health ConditionsCOVID Deaths Continue to Decline in U.S.Researchers Seek Antiviral Pill That Would Ease COVID SeverityAHA News: Take Stock of Your Health With This Post-Lockdown ChecklistPoll Reveals Who's Most Vaccine-Hesitant in America and WhyGood Stroke Recovery May Depend on Your ZIP Code: StudyNew Advice for Blood Pressure That's a Bit Too HighCOVID-19 and Advanced Diabetes Can Be a Deadly Mix: StudyMany U.S. Colleges Will Mandate Vaccines on Campus Next Fall: SurveyPfizer/Moderna Vaccine Protection: 64% at First Dose, 94% at SecondAbout 1 in 7 Who Get Pfizer Vaccine Will Have Any 'Systemic' Side Effect: StudyPolls Find Most U.S. Young People Take COVID Threat Seriously
Questions and AnswersLinks
Related Topics

Diabetes

Chinese COVID Vaccine Appears Safe, Effective

HealthDay News
by Robert Preidt
Updated: Nov 18th 2020

new article illustration

WEDNESDAY, Nov. 18, 2020 (HealthDay News) -- A Chinese COVID-19 vaccine seems to be safe and effective, early trial results suggest, but one expert says the findings should be regarded with caution.

The CoronaVac vaccine is based on inactivated SARS-CoV-2 virus. It was tested in a phase 1/2 clinical trial that included more than 700 healthy volunteers, ages 18-59, who were recruited in China between April 16 and May 5.

The vaccine appeared to be safe and well-tolerated at all tested doses, researchers reported. The most common reported side effect was pain at the injection site.

Even at the lowest dose tested (3 micrograms), participants had strong antibody responses within two weeks of the second and final dose. Shots were given 14 days apart.

Though levels of antibodies triggered by the vaccine were lower than those in recovered coronavirus patients, researchers said they still believe the vaccine could provide protection from the virus.

They noted that the trial's primary objective was to evaluate the vaccine's immune response and safety. It wasn't designed to assess how effective the vaccine is in preventing infection with SARS-CoV-2.

The findings were published Nov. 17 in The Lancet Infectious Diseases journal.

After taking into account side effects and other factors, the researchers determined that a dose of 3 mcg prompted the highest antibody response. This will be investigated further in phase 3 trials now underway.

"Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunization by giving two doses of the vaccine at a 14-day interval. We believe that this makes the vaccine suitable for emergency use during the pandemic," said co-lead author Fengcai Zhu of the Jiangsu Provincial Center for Disease Control and Prevention in Nanjing, China.

"In the longer term, when the risk of COVID-19 is lower, our findings suggest that giving two doses with a one-month interval, rather than a two-week interval, might be more appropriate for inducing stronger and potentially longer-lasting immune responses. However, further studies are needed to check how long the antibody response remains after either vaccination schedule," Zhu said in a journal news release.

CoronaVac is one of 48 COVID-19 vaccine candidates now in clinical trials.

Naor Bar-Zeev, an associate professor in the Division of Global Disease Epidemiology and Control at Johns Hopkins University in Baltimore, wrote an editorial that accompanied the findings.

"Like all phase 2 trials, the results must be interpreted with caution until phase 3 results are published," he wrote. "But even then, after phase 3 trial completion and after licensure, we should prudently remain cautious."

More information

For more on COVID-19 vaccines, go to the U.S. Centers for Disease Control and Prevention.

SOURCE: The Lancet Infectious Diseases, news release, Nov. 17, 2020